Analgesics in Japan is set to exhibit minimal growth in 2026, with value sales reaching JPY197 billion and a rise of only 0.4% over the previous year, contrasting with more dynamic patterns in other Asia Pacific markets. The environment is defined by its maturity, with little prospect for expansion in volume due to a declining population and already widespread adoption of self-medication. Despite these demographic headwinds, analgesics remains attractive for brands capable of commanding premium pricing, as consumers continue to spend robustly on health and wellbeing, evidenced by a rise in consumer expenditure. Success now hinges on advanced product development, rapid relief solutions and strategic positioning within trusted retail channels, as growth will be realised through value rather than volume. Brands that invest in scientific innovation, communicate product benefits clearly and leverage established pharmacy networks will be best placed to defend and grow share in an increasingly competitive, value-driven environment.
Delivery:
Files are delivered directly into your account soon after payment is received and any tax is certification is verified (where applicable).
This report comes in PDF with additional info in Excel included.
Overview:
Understand the latest market trends and future growth opportunities for the Analgesics industry in Japan with research from Euromonitor International's team of in-country analysts – experts by industry and geographic specialisation.
Key trends are clearly and succinctly summarised alongside the most current research data available. Understand and assess competitive threats and plan corporate strategy with our qualitative analysis, insight and confident growth projections.
If you're in the Analgesics industry in Japan, our research will help you to make informed, intelligent decisions; to recognise and profit from opportunity, or to offer resilience amidst market uncertainty.
The Analgesics in Japan report includes:
- Analysis of key supply-side and demand trends
- Detailed segmentation of international and local products
- Historic volume and value sizes, company and brand market shares
- Five year forecasts of market trends and market growth
- Robust and transparent research methodology, conducted in-country
This report answers:
- What is the market size of Analgesics in Japan?
- Which are the leading brands in Analgesics in Japan?
- How are products distributed in Analgesics in Japan?
- How has the regulatory and operating environment for Analgesics changed in Japan?
- How are considerations such as stress, self-medication and shifting consumer lifestyles shaping demand for Analgesics
- How significant are wider health concerns and consumer awareness in determining sales?
- Where is future growth expected to be most dynamic?
Key Data Insights
Key Industry Trends
Brands drive premiumisation as volume growth stalls
Government reforms prompt self-medication, but impact remains limited
Innovation sustains resilience in a shrinking market
Chart 1 Value Sales 2021-2031
Chart 2 Value Sales by Category 2026
Premiumisation drives value growth as ageing population affects demand
Targeted relief and innovation secure topical formats’ leadership
Innovation and changing policy reinforce the role of consumer trust
Chart 1 Forecast Value Sales 2021-2031
Chart 2 Forecast Value Sales by Category 2026-2031
Hisamitsu, Daiichi Sankyo and SSP sustain leadership as rivals focus on premium features
Suntory’s acquisition and targeted launches reshape self-care strategies
Chart 1 Company Shares 2026
Chart 2 Brand Shares 2026
Health and beauty specialists sustain consumer trust with immediate access
Online sales expand, but offline channels remain indispensable
Chart 1 Retail Channels 2021-2026
SSP and Haleon focus on rapid relief to drive premium sales
Daiichi Sankyo expands convenience with targeted launch
Policy changes prompt self-care, but reinforce stability for trusted brands
Chart 1 Real GDP Growth 2021-2031
Chart 2 Inflation 2021-2031
Chart 1 Population 2021-2031
Chart 2 Population by Generation 2026
Chart 3 Consumer Expenditure 2021-2031
Country Reports Disclaimer
The following categories and subcategories are included:
Analgesics
-
-
- Adult Acetaminophen
- Adult Aspirin
- Adult Combination Products - Analgesics
- Adult Diclofenac
- Adult Dipyrone
- Adult Ibuprofen
- Adult Ketoprofen
- Adult Naproxen
- Adult OTC Triptans
-
- Paediatric Acetaminophen
- Paediatric Aspirin
- Paediatric Combination Products - Analgesics
- Paediatric Dipyrone
- Paediatric Ibuprofen
- Paediatric Naproxen
-
- Acetaminophen
- Aspirin
- Combination Products - Analgesics
- Diclofenac
- Dipyrone
- Ibuprofen
- Ketoprofen
- Naproxen
- OTC Triptans
-
- Topical Analgesics/Anaesthetic
Analgesics
Analgesics cover systemic and topical pain relievers. Products which include a pain-relief ingredient in addition to another core function are excluded (e.g. a sore throat remedy which includes paracetamol is excluded from the analgesics and instead is included in pharyngeal remedies).
See all of our definitionsWhy buy this report?
- Gain competitive intelligence about market leaders
- Track key industry trends, opportunities and threats
- Inform your marketing, brand, strategy and market development, sales and supply functions
This report originates from Passport, our Analgesics research and analysis database.
NEW REPORT GUARANTEE
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extraction Free!